Dianthus Therapeutics (DNTH) Cash from Financing Activities (2017 - 2025)

Dianthus Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $274.5 million for Q3 2025.

• In Q3 2025, Cash from Financing Activities rose 92640.88% year-over-year to $274.5 million; the TTM figure through Sep 2025 stood at $314.9 million (up 49.19% YoY), while the FY2024 annual figure was $255.6 million, up 91.37% from the prior year.
• Cash from Financing Activities was $274.5 million for Q3 2025 at Dianthus Therapeutics, up from $568000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $274.5 million in Q3 2025 to a low of -$4.9 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $56.7 million across 5 years, with a median of $418000.0 in 2021.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities plunged 99.94% in 2022, then surged 92640.88% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $124000.0 in 2021, then jumped by 77825.0% to $96.6 million in 2022, then tumbled by 105.03% to -$4.9 million in 2023, then soared by 915.54% to $39.7 million in 2024, then jumped by 591.89% to $274.5 million in 2025.
• The last three Cash from Financing Activities figures came in at $274.5 million (Q3 2025), $568000.0 (Q2 2025), and $161000.0 (Q1 2025), per Business Quant data.